Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
Tóm tắt
Từ khóa
Tài liệu tham khảo
Coleman, 2006, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin. Cancer Res., 12, 6243s, 10.1158/1078-0432.CCR-06-0931
Mundy, 2002, Metastasis to bone: causes, consequences and therapeutic opportunities, Nat. Rev. Cancer, 2, 584, 10.1038/nrc867
Futakuchi, 2016, Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer, Adv. Drug Deliv. Rev., 99, 206, 10.1016/j.addr.2015.11.017
Wu, 2016, Patterns of distant metastasis in Chinese women according to breast cancer subtypes, Oncotarget, 7, 47975, 10.18632/oncotarget.10099
Yoneda, 2005, Crosstalk between cancer cells and bone microenvironment in bone metastasis, Biochem. Biophys. Res. Commun., 328, 679, 10.1016/j.bbrc.2004.11.070
Yoneda, 2001, A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro, J. Bone Miner. Res., 16, 1486, 10.1359/jbmr.2001.16.8.1486
Yeung, 2016, Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review, Cancer Metastasis Rev., 35, 427, 10.1007/s10555-016-9631-3
Lee, 2011, Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer, Cancer Res. Treat., 43, 89, 10.4143/crt.2011.43.2.89
Harbeck, 2012, Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer, J. Clin. Oncol., 30, 686, 10.1200/JCO.2011.38.9619
van Kruchten, 2013, PET imaging of oestrogen receptors in patients with breast cancer, Lancet Oncol., 14, e465, 10.1016/S1470-2045(13)70292-4
Kurland, 2020, Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16alpha-18F-fluoro-17beta-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications, Oncologist, 25, 835, 10.1634/theoncologist.2019-0967
van Kruchten, 2012, PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma, J. Nucl. Med., 53, 182, 10.2967/jnumed.111.092734
Nienhuis, 2018, (18)F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients, J. Nucl. Med., 59, 1212, 10.2967/jnumed.117.198846
Gupta, 2017, Can (18)F-fluoroestradiol positron emission tomography become a new imaging standard in the estrogen receptor-positive breast cancer patient: a prospective comparative study with (18)F-fluorodeoxyglucose positron emission tomography?, World J. Nucl. Med., 16, 133, 10.4103/1450-1147.203071
van Kruchten, 2015, Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy, Eur. J. Nucl. Med. Mol. Imaging, 42, 1674, 10.1007/s00259-015-3107-5
Hogan, 2015, Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma, J. Nucl. Med., 56, 1674, 10.2967/jnumed.115.161455
Kurland, 2017, Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer, Clin. Cancer Res., 23, 407, 10.1158/1078-0432.CCR-16-0362
Boellaard, 2015, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur. J. Nucl. Med. Mol. Imaging, 42, 328, 10.1007/s00259-014-2961-x
Piccardo, 2015, 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT, Nuklearmedizin, 54, 163, 10.3413/Nukmed-0727-15-02
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Piccardo, 2020, Diagnosis, treatment response, and prognosis: the role of (18)F-DOPA PET/CT in children affected by neuroblastoma in comparison with (123)I-mIBG scan: the first prospective study, J. Nucl. Med., 61, 367, 10.2967/jnumed.119.232553
Ueda, 2008, Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer, Jpn. J. Clin. Oncol., 38, 250, 10.1093/jjco/hyn019
Ulaner, 2013, Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer, Cancer Med., 2, 725, 10.1002/cam4.119
Mortimer, 1996, Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy, Clin. Cancer Res., 2, 933
Linden, 2006, Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer, J. Clin. Oncol., 24, 2793, 10.1200/JCO.2005.04.3810
Venema, 2017, Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies, J. Nucl. Med., 58, 1906, 10.2967/jnumed.117.193649
Chae, 2017, A randomized feasibility study of (18)F-fluoroestradiol PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer, J. Nucl. Med., 58, 563, 10.2967/jnumed.116.178368
Liu, 2019, (18)F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with (18)F-FDG PET/CT, Oncologist, 24, e1277, 10.1634/theoncologist.2019-0096